We are ramping up our industrial development with the inauguration in France of a new production unit for the active ingredient of one of our medicine. This major investment, undertaken at our main production site in Normandy (France), is part of our Servier 2030 strategic plan. Our aim is to increase and secure our production capacity for active ingredients to meet the growing needs of patients living with venous disease worldwide.
A timely response to the growing needs of patients worldwide
Venous diseases are among the most common diseases in the world, affecting around 30% of the world’s population, or 2.2 billion patients.1 Furthermore, the incidence of venous diseases is increasing by 4% each year2, with the highest prevalence in Eastern Europe and Latin America (nearly 70%).3 Current estimates indicate that the number of patients still untreated exceeds 30%.4
A bold investment in an innovative and industrial transformation project
Therefore, with a view to fulfilling the growing need for therapeutic solutions in the treatment of venous diseases, we have invested €150 million to develop a new manufacturing process and build a new production unit. Part of the investment was dedicated to the construction of a methanization plant to recycle processed waste into gas, thus enabling the unit to be nearly self-sufficient in terms of energy requirements. In addition, an effluent treatment plant was installed to reduce the site’s environmental footprint through a greener, cleaner, and more autonomous treatment cycle.
“These new industrial facilities mark a strategic step in line with our 2030 ambition. By combining innovation and industrial excellence, we are scaling up our ability to sustainably meet patient needs, while bolstering our health sovereignty in France and Europe.”
Olivier Laureau, President of Servier
Alongside this new production unit in Normandy, we have also invested €80 million in our industrial site in Budapest, Hungary, where a second production unit for this same active ingredient is being built. Between 2019 and 2025, the Group has invested more than €230 million to expand capacity for the production of active ingredients in Europe, positioning itself as one of the leading French pharmaceutical companies with regard to industrial investment, affirming the company’s local roots, and demonstrating its commitment to boosting Europe’s healthcare autonomy.
[1] Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2021
[2] Lee AJ, Robertson LA, Boghossian SM, Allan PL, Ruckley CV, Fowkes FG, et al. Progression of varicose veins and chronic venous insufficiency in the general population in the Edinburgh Vein Study. J Vasc Surg Venous Lymphat Disord. 2015;3(1):18–26. doi: 10.1016/j.jvsv.2014.09.008.
[3] Vuylsteke ME, et al. Angiology. 2018;69(9):779-785; Salim S, et al. Global Ann Surg. 2021;274(6):971-976.
NA not available data
[4] Performance Trackers CVD 2019 & 2021 and HD 2020. Patient Pathway 2018